Xolair 150 mg (Omalizumab 150 mg) by Novartis.
Indications: Severe persistent allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps and IgE-mediated food allergy (per market).
Administration: Subcutaneous injection every 2–4 weeks; dose by IgE level and body weight.
Storage: Store in a refrigerator at 2–8 °C. Do not freeze. Keep in the outer carton to protect from light.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Novartis |
| Active ingredient | Omalizumab 150 mg — anti-IgE monoclonal antibody. |
| Strength & pack | 1 pre-filled syringe/pen (or vial of powder). |
| Form | Solution for injection |
| Storage | Store in a refrigerator at 2–8 °C. Do not freeze. Keep in the outer carton to protect from light. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |